The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia (Q24187297)

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Improved treatment results in children with AML: Results of study AML-BFM 93

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Treatment of acute myeloblastic leukemia in adults. The GOELAM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin cardiotoxicity in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

3 × 14 mg/m2 Idarubicin during induction: results of a pilot study in children with AML

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin including regimens in acute myelogenous leukemia in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Therapeutic advances in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Acute myeloid leukemia: epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Anthracycline dose intensification in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

The prevention and treatment of missing data in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Phase I trial of 4-demethoxydaunorubicin with single i.v. doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Ad

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Oral idarubicin in elderly patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Antileukemic activity of 4-demethoxydaunorubicin in mice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010432.PUB2

7 January 2021

10.1002/14651858.CD010432.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4707046

OpenCitations bibliographic resource ID

4707046

1 reference